Haemonetics Corporation $HAE Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC boosted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 47.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 42,163 shares of the medical instruments supplier’s stock after purchasing an additional 13,553 shares during the period. Peregrine Capital Management LLC owned approximately 0.09% of Haemonetics worth $2,376,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth $26,000. True Wealth Design LLC increased its position in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the period. Leonteq Securities AG purchased a new position in Haemonetics in the 4th quarter worth $30,000. EverSource Wealth Advisors LLC raised its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Haemonetics during the 4th quarter worth about $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. JPMorgan Chase & Co. dropped their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. BTIG Research reiterated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research report on Friday, June 26th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, Robert W. Baird set a $67.00 price target on shares of Haemonetics in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.33.

Haemonetics Stock Up 0.1%

Shares of HAE opened at $74.93 on Friday. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of 37.09, a PEG ratio of 1.51 and a beta of 0.52. The stock’s 50-day moving average price is $66.55 and its 200-day moving average price is $66.49.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same period last year, the business earned $1.24 earnings per share. Haemonetics’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, sell-side analysts predict that Haemonetics Corporation will post 5.22 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.